Beta

Pulmonx corporationLUNG.US Overview

US StockHealthcare
(No presentation for LUNG)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

LUNG AI Insights

LUNG Overall Performance

LUNG AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LUNG Recent Performance

-3.91%

Pulmonx corporation

-1.10%

Avg of Sector

-0.49%

S&P500

LUNG PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check LUNG's Trend

LUNG Key Information

LUNG Valuation Metrics

LUNG Profile

Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Price of LUNG

LUNG FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LUNG Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.28
PE Ratio (TTM)
-
Forward PE
28.33
PS Ratio (TTM)
0.59
PB Ratio
1.00
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
74.19%
Net Margin
-59.67%
Revenue Growth (YoY)
8.01%
Profit Growth (YoY)
8.29%
3-Year Revenue Growth
13.57%
3-Year Profit Growth
16.19%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.28
PE Ratio (TTM)
-
Forward PE
28.33
PS Ratio (TTM)
0.59
PB Ratio
1.00
Price-to-FCF
-
Gross Margin
74.19%
Net Margin
-59.67%
Revenue Growth (YoY)
8.01%
Profit Growth (YoY)
8.29%
3-Year Revenue Growth
13.57%
3-Year Profit Growth
16.19%
  • When is LUNG's latest earnings report released?

    The most recent financial report for Pulmonx corporation (LUNG) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LUNG's short-term business performance and financial health. For the latest updates on LUNG's earnings releases, visit this page regularly.

  • What is the operating profit of LUNG?

    According to the latest financial report, Pulmonx corporation (LUNG) reported an Operating Profit of -9.9M with an Operating Margin of -43.82% this period, representing a growth of 26.19% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is LUNG's revenue growth?

    In the latest financial report, Pulmonx corporation (LUNG) announced revenue of 22.6M, with a Year-Over-Year growth rate of -4.91%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does LUNG have?

    As of the end of the reporting period, Pulmonx corporation (LUNG) had total debt of 56.36M, with a debt ratio of 0.44. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does LUNG have?

    At the end of the period, Pulmonx corporation (LUNG) held Total Cash and Cash Equivalents of 70.01M, accounting for 0.54 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does LUNG go with three margins increasing?

    In the latest report, Pulmonx corporation (LUNG) did not achieve the “three margins increasing” benchmark, with a gross margin of 77.6%%, operating margin of -43.82%%, and net margin of -46.1%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess LUNG's profit trajectory and future growth potential.

  • Is LUNG's EPS continuing to grow?

    According to the past four quarterly reports, Pulmonx corporation (LUNG)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.25. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LUNG?

    Pulmonx corporation (LUNG)'s Free Cash Flow (FCF) for the period is -7.1M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 3.74% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of LUNG?

    The latest valuation data shows Pulmonx corporation (LUNG) has a Price-To-Earnings (PE) ratio of -1.4 and a Price/Earnings-To-Growth (PEG) ratio of 0.08. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.